Cited by 34Drug Transport and Resistance MechanismsPhotodynamic Therapy Research StudiesPorphyrin Metabolism and Disorders

The DOI matches its Crossref record.

Cellular Phototoxicity Evoked Through the Inhibition of Human ABC Transporter ABCG2 by Cyclin-dependent Kinase Inhibitors In vitro

Abstract

Purpose The physiological importance of the human ATP-binding cassette (ABC) transporter ABCG2 has been recognized with regard to porphyrin-mediated photosensitivity. Functional impairment owing to inhibition of ABCG2 by drugs or its genetic polymorphisms may lead to the disruption of porphyrin homeostasis, which in turn causes cellular toxicity. Materials and methods We evaluated the impact on photosensitivity of the inhibition by cyclin-dependent kinase (CDK) inhibitors of ABCG2 function. For this purpose, we established new methods for photosensitivity assays by using Flp-In-293 cells and plasma membrane vesicles prepared from Sf9 insect cells. With the new methods, we subsequently tested CDK inhibitors, i.e., purvalanol A, WHI-P180, bohemine, roscovitine, and olomoucine. Results Among CDK inhibitors tested, purvalanol A was found to be the most potent inhibitor (IC50=3.5 microM) for ABCG2-mediated hematoporphyrin transport. At a concentration of 2.5 microM, it evoked the photosensitivity of ABCG2-expressing Flp-In-293 cells treated with pheophorbide a. WHI-P180 moderately inhibited ABCG2 function, exhibiting weak phototoxicity. In contrast, the phototoxicity of bohemine, roscovitine, and olomoucine were minimal in our assay system. Conclusions It is suggested that the planar structure is an important factor for interactions with the active site of ABCG2. The present study provides a new approach to studying drug-induced phototoxicity in vitro.

Overview

Integrity signals

Registry

Crossref · 10.1007/s11095-008-9738-5

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 29

  1. J. W. Jonker, S. Musters, M. L. Vlaming, T. Plosch, K. E. Gooijert, M. J. Hillebrand, H. Rosing, J. H. Beijnen, H. J. Verkade, and A. H. Schinkel. Breast cancer resistance protein (Bcrp1/Abcg2) is expressed in the harderian gland and mediates transport of conjugated protoporphyrin IX. Am. J. Physiol. Cell. Physiol. 292:C2204–2212 (2007). doi:10.1152/ajpcell.00359.2006. · DOI
  2. J. W. Jonker, M. Buitelaar, E. Wagenaar, M. A. Van Der Valk, G. L. Scheffer, R. J. Scheper, T. Plosch, F. Kuipers, R. P. Elferink, H. Rosing, J. H. Beijnen, and A. H. Schinkel. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl. Acad. Sci. U.S.A. 99:15649–15654 (2002). doi:10.1073/pnas.202607599. · DOI · Paper page
  3. A. Tamura, M. Watanabe, H. Saito, H. Nakagawa, T. Kamachi, I. Okura, and T. Ishikawa. Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport. Mol. Pharmacol. 70:287–296 (2006). · DOI · Paper page
  4. A. Tamura, Y. Onishi, R. An, S. Koshiba, K. Wakabayashi, K. Hoshijima, W. Priebe, T. Yoshida, S. Kometani, T. Matsubara, K. Mikuriya, and T. Ishikawa. In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs. Drug Metab. Pharmacokinet. 22:428–440 (2007). doi:10.2133/dmpk.22.428. · DOI · Paper page
  5. R. Allikmets, L. M. Schriml, A. Hutchinson, V. Romano-Spica, and M. Dean. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 58:5337–5339 (1998).
  6. L. A. Doyle, W. Yang, L. V. Abruzzo, T. Krogmann, Y. Gao, A. K. Rishi, and D. D. Ross. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA. 95:15665–15670 (1998). doi:10.1073/pnas.95.26.15665. · DOI
  7. K. Miyake, L. Mickley, T. Litman, Z. Zhan, R. Robey, B. Cristensen, M. Brangi, L. Greenberger, M. Dean, T. Fojo, and S. E. Bates. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 59:8–13 (1999).
  8. M. Maliepaard, M. A. van Gastelen, L. A. de Jong, D. Pluim, R. C. van Waardenburg, M. C. Ruevekamp-Helmers, B. G. Floot, and J. H. Schellens. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res. 59:4559–4563 (1999).
  9. D. D. Ross, W. Yang, L. V. Abruzzo, W. S. Dalton, E. Schneider, H. Lage, M. Dietel, L. Greenberger, S. P. Cole, and L. A. Doyle. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J. Natl. Cancer Inst. 91:429–433 (1999). doi:10.1093/jnci/91.5.429. · DOI
  10. M. Brangi, T. Litman, M. Ciotti, K. Nishiyama, G. Kohlhagen, C. Takimoto, R. Robey, Y. Pommier, T. Fojo, and S. E. Bates. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res. 59:5938–5946 (1999).
  11. S. Kawabata, M. Oka, K. Shiozawa, K. Tsukamoto, K. Nakatomi, H. Soda, M. Fukuda, Y. Ikegami, K. Sugahara, Y. Yamada, S. Kamihira, L. A. Doyle, D. D. Ross, and S. Kohno. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem. Biophys. Res. Commun. 280:1216–1223 (2001). doi:10.1006/bbrc.2001.4267. · DOI
  12. S. Koshiba, R. An, H. Saito, K. Wakabayashi, A. Tamura, and T. Ishikawa. Human ABC transporters ABCG2 (BCRP) and ABCG4. Xenobiotica 38:863–888(2008). · DOI
  13. P. Krishnamurthy, T. Xie, and J. D. Schuetz. The role of transporters in cellular heme and porphyrin homeostasis. Pharmacol. Ther. 114:345–358 (2007). doi:10.1016/j.pharmthera.2007.02.001. · DOI
  14. K. Wakabayashi, A. Tamura, H. Saito, Y. Onishi, and T. Ishikawa. Human ABC transporter ABCG2 in xenobiotic protection and redox biology. Drug Metab. Rev. 38:371–391 (2006). doi:10.1080/03602530600727947. · DOI · Paper page
  15. P. Rousselot, J. Larghero, E. Raffoux, F. Calvo, M. Tulliez, S. Giraudier, and M. Rybojad. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate. Br. J. Haematol. 120:1091–1092 (2003). doi:10.1046/j.1365-2141.2003.04208_3.x. · DOI
  16. V. Brazzelli, F. Prestinari, T. Barbagallo, C. Rona, E. Orlandi, F. Passamonti, F. Locatelli, M. Zecca, S. Villani, and G. Borroni. A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients. J. Eur. Acad. Dermatol. Venereol. 21:384–387 (2007). doi:10.1111/j.1468-3083.2006.01981.x. · DOI
  17. C. Ozvegy-Laczka, T. Hegedus, G. Varady, O. Ujhelly, J. D. Schuetz, A. Varadi, G. Keri, L. Orfi, K. Nemet, and B. Sarkadi. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol. Pharmacol. 65:1485–1495 (2004). doi:10.1124/mol.65.6.1485. · DOI
  18. H. Saito, H. Hirano, H. Nakagawa, T. Fukami, K. Oosumi, K. Murakami, H. Kimura, T. Kouchi, M. Konomi, E. Tao, N. Tsujikawa, S. Tarui, M. Nagakura, M. Osumi, and T. Ishikawa. A new strategy of high-speed screening and quantitative structure–activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions. J. Pharmacol. Exp. Ther. 317:1114–1124 (2006). doi:10.1124/jpet.105.099036. · DOI · Paper page
  19. J. Dancey, and E. A. Sausville. Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discov. 2:296–313 (2003). doi:10.1038/nrd1066. · DOI
  20. P. M. Nurse. Nobel Lecture. Cyclin dependent kinases and cell cycle control. Biosci. Rep. 22:487–499 (2002). doi:10.1023/A:1022017701871. · DOI
  21. P. L. Porter, K. E. Malone, P. J. Heagerty, G. M. Alexander, L. A. Gatti, E. J. Firpo, J. R. Daling, and J. M. Roberts. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 3:222–225 (1997). doi:10.1038/nm0297-222. · DOI
  22. J. Tsihlias, L. Kapusta, and J. Slingerland. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu. Rev. Med. 50:401–423 (1999). doi:10.1146/annurev.med.50.1.401. · DOI
  23. A. Tamura, K. Wakabayashi, Y. Onishi, H. Nakagawa, M. Tsuji, Y. Matsuda, and T. Ishikawa. Genetic polymorphisms of human ABC transporter ABCG2: development of the standard method for functional validation of SNPs by using the Flp recombinase system. J. Exp. Ther. Oncol. 6:1–11 (2006).
  24. A. Tamura, K. Wakabayashi, Y. Onishi, M. Takeda, Y. Ikegami, S. Sawada, M. Tsuji, Y. Matsuda, and T. Ishikawa. Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2. Cancer Sci. 98:231–239 (2007). doi:10.1111/j.1349-7006.2006.00371.x. · DOI
  25. K. Wakabayashi, H. Nakagawa, A. Tamura, S. Koshiba, K. Hoshijima, M. Komada, and T. Ishikawa. Intramolecular disulfide bond is a critical check point determining degradative fates of ATP-binding cassette (ABC) transporter ABCG2 protein. J. Biol. Chem. 282:27841–27846 (2007). doi:10.1074/jbc.C700133200. · DOI
  26. M. E. Noble, J. A. Endicott, and L. N. Johnson. Protein kinase inhibitors: insights into drug design from structure. Science. 303:1800–1805 (2004). doi:10.1126/science.1095920. · DOI
  27. N. B. Elkind, Z. Szentpetery, A. Apati, C. Ozvegy-Laczka, G. Varady, O. Ujhelly, K. Szabo, L. Homolya, A. Varadi, L. Buday, G. Keri, K. Nemet, and B. Sarkadi. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res. 65:1770–1777 (2005). doi:10.1158/0008-5472.CAN-04-3303. · DOI
  28. D. E. MacCallum, J. Melville, S. Frame, K. Watt, S. Anderson, A. Gianella-Borradori, D. P. Lane, and S. R. Green. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res. 65:5399–5407 (2005). doi:10.1158/0008-5472.CAN-05-0233. · DOI
  29. H. Saito, H. Hirano, and T. Ishikawa. High-speed screening and quantitative SAR analysis of human ABC transporter ABCG2 for molecular modeling of anticancer drugs to circumvent multidrug resistance. Mini Rev. Med. Chem. 7:1009–1018 (2007). doi:10.2174/138955707782110169. · DOI

Cited by

Sorted by citations

Metadata

Authors
An, R., Hagiya, Y., Tamura, A., Li, S., Saito, H., Tokushima, D., & Ishikawa, T.
Affiliations
  • Tokyo Institute of Technology (JP)
  • NEC (Japan) (JP)
Corresponding author
Ishikawa, Toshihisa
Venue
Pharmaceutical Research
Published
2008-10-09
Volume
26
Issue
2
Pages
449-458
ISSN
  • 0724-8741 (ISSN-L)
  • 1573-904X
OpenAlex
W1997743873
Cited by
34
References
0
Citations by year
2024: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 4 · 2016: 1 · 2015: 2 · 2014: 2 · 2013: 5 · 2012: 1
FWCI
1.99
Type
journal article
Language
en
Open access
closed
Locations
  • Pharmaceutical Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
Japan Society for the Promotion of Science
Topics
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Porphyrin Metabolism and Disorders
Keywords
ABCG2, ABC transporters, phototoxicity, cyclin-dependent kinase inhibitors, purvalanol A, pheophorbide a, drug-induced phototoxicity, plasma membrane vesicles, drug-transporter interactions
MeSH terms
ATP Binding Cassette Transporter, Subfamily G, Member 2, Roscovitine, Animals, Cell Line, Cell Membrane, Cell Survival, Chlorophyll, Dose-Response Relationship, Drug, Hematoporphyrins, Humans, Kinetin, Models, Molecular, Molecular Conformation, Neoplasm Proteins, Purines, Quinazolines, Transfection, Molecular Structure, Photosensitizing Agents, Spodoptera, ATP-Binding Cassette Transporters, Cyclin-Dependent Kinases, Quantitative Structure-Activity Relationship, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review